Who Generates Higher Gross Profit? Takeda Pharmaceutical Company Limited or Veracyte, Inc.

Takeda vs. Veracyte: A Gross Profit Comparison

__timestampTakeda Pharmaceutical Company LimitedVeracyte, Inc.
Wednesday, January 1, 2014125683400000021584000
Thursday, January 1, 2015127197300000028006000
Friday, January 1, 2016117329600000039623000
Sunday, January 1, 2017127461000000043758000
Monday, January 1, 2018143753400000058930000
Tuesday, January 1, 2019220142400000083845000
Wednesday, January 1, 2020220350400000076028000
Friday, January 1, 20212462160000000145114000
Saturday, January 1, 20222783406000000194954000
Sunday, January 1, 20232832257000000248148000
Monday, January 1, 20242832257000000
Loading chart...

Infusing magic into the data realm

A Tale of Two Companies: Gross Profit Showdown

In the competitive world of pharmaceuticals and diagnostics, Takeda Pharmaceutical Company Limited and Veracyte, Inc. stand as intriguing case studies. Over the past decade, Takeda has consistently outperformed Veracyte in terms of gross profit. From 2014 to 2023, Takeda's gross profit surged by approximately 125%, peaking at an impressive 2.83 trillion yen in 2023. In contrast, Veracyte's growth, while notable, was more modest, with a 1050% increase, reaching 248 million dollars in the same year.

The Bigger Picture

Takeda's dominance is evident, with its gross profit figures dwarfing those of Veracyte by a factor of over 10,000. This disparity highlights the scale and reach of Takeda's operations compared to the more niche focus of Veracyte. However, the absence of data for 2024 suggests a potential shift or anomaly worth monitoring.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025